Key result
Patients with refractory unstable angina pectoris had significantly higher baseline levels of CCL18 (104.4 vs 53.7 ng/mL, P=0.011) and CCL5 (32.7 vs 23.1 ng/mL, P=0.018) than stabilized patients.
Why the study?
Are elevated levels of CCL5 and CCL18 associated with refractory symptoms and future cardiovascular adverse events in patients with unstable angina pectoris?
Cohort (n=54)
Are elevated levels of CCL5 and CCL18 associated with refractory symptoms and future cardiovascular adverse events in patients with unstable angina pectoris?
CCL5 and CCL18 are transiently elevated during unstable angina pectoris and may serve as specific markers for refractory symptoms and future cardiovascular events.
Answers are grounded in this paper and cite their sources.
Higher CCL18/CCL5 levels were associated with refractory unstable angina; leaves open their value as prognostic biomarkers.
BACKGROUND: Chemokines play an important role in atherogenesis and in ischemic injury and repair; however, prospective data on individual chemokines in unstable angina pectoris (UAP) are scarce. Therefore, we assessed chemokine patterns in a prospective cohort of patients with UAP. METHODS AND RESULTS: Plasma samples of 54 patients with Braunwald class IIIB UAP were examined at baseline for 11 chemokines and 5 inflammatory mediators via multiplex analysis. Levels of CC chemokine ligand (CCL)-5 (also known as RANTES [regulated on activation, normally T-cell expressed, and secreted]; 32.7 versus 23.1 ng/mL, P=0.018) and CCL18 (also known as PARC [pulmonary and activation-regulated chemokine]; 104.4 versus 53.7 ng/mL, P=0.011) were significantly elevated in patients with refractory ischemic symptoms versus stabilized patients. Temporal monitoring by ELISA of CCL5, CCL18, and soluble CD40 ligand (sCD40) levels revealed a drop in CCL5 and sCD40L levels in all UAP patients from day 2 onward (CCL5 12.1 ng/mL, P<0.001; sCD40L 1.35 ng/mL, P<0.05), whereas elevated CCL18 levels were sustained for at least 2 days, then were decreased at 180 days after inclusion (34.5 ng/mL, P<0.001). Peripheral blood mononuclear cells showed increased protein expression of chemokine receptors CCR3 and CCR5 in CD3+ and CD14+ cells at baseline compared with 180 days after inclusion, whereas mRNA levels were downregulated, which was attributable in part to a postischemic release of human neutrophil peptide-3-positive neutrophils and in part to negative feedback. Finally, elevated CCL5 and CCL18 levels predicted future cardiovascular adverse events, whereas C-reactive protein and sCD40L levels did not. CONCLUSIONS: We are the first to report that CCL18 and CCL5 are transiently raised during episodes of UAP, and peak levels of both chemokines are indicative of refractory symptoms. Because levels of both chemokines, as well as of cognate receptor expression by circulating peripheral blood mononuclear cells, are increased during cardiac ischemia, this may point to an involvement of CCL5/CCL18 in the pathophysiology of UAP and/or post-UAP responses.
No takes yet. Share an insight, caveat, or question.
Kraaijeveld et al. (2007) conducted a cohort in Unstable angina pectoris (n=54). Refractory ischemic symptoms vs. Stabilized patients was evaluated on CCL18 levels (ng/mL) (p=0.011). Patients with refractory unstable angina pectoris had significantly higher baseline levels of CCL18 (104.4 vs 53.7 ng/mL, P=0.011) and CCL5 (32.7 vs 23.1 ng/mL, P=0.018) than stabilized patients.
Synapse has enriched 10 related papers. Consider them for comparative context: